Peregrine reports top-line data from Phase III SUNRISE Trial
Peregrine Pharmaceuticals reported that top-line data from the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer, or NSCLC, were presented in an oral presentation at the European Society for Medical Oncology 2016 Congress. The presentation included interim efficacy and safety outcomes, as well as initial findings from the company's ongoing biomarker analysis of samples collected during the study. The SUNRISE Phase III trial was discontinued earlier this year based on a pre-specified interim analysis although patient treatment and follow-up in the study were allowed to continue. The pre-planned biomarker analysis has been taking place as patient follow-up has continued and available results were evaluated as part of the recent top-line data analysis. The study protocol pre-specified the collection of thousands of patient samples for exploratory analyses over a wide range of possible biomarkers, including pre-treatment levels of beta-2 glycoprotein-1.